China's R&D Outsourcing Market Reaches $315 Million, Expected To Maintain High Growth Through 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
IPO for ShangPharma, China's second-largest CRO after the leading WuXi PharmaTech, debuted Oct. 19.
You may also be interested in...
Asia Spotlight: China's Top Drug Distributors Are Soaring
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
Deals Of The Week: Sanofi-Aventis/Stanford, Ariad/ReGenX, Baxter/Prism
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
China Releases New Drug GMPs; Domestic Consolidation Expected
SHANGHAI – China’s State FDA released its long-awaited good manufacturing practice guidelines for pharmaceutical products Feb. 12.